The soft no dictionary: what VCs and pharma BD actually mean
A translation guide to the phrases VCs and pharma BD teams use instead of saying no, and which ones a better equity story could have prevented.
In twenty years of watching biotech deals move, stall, and occasionally close, I have never once heard a venture capitalist say no.
This is not because they always say yes. It is because they have developed an entire vocabulary to avoid the word entirely. Pharma BD teams have done the same, independently, and arrived at a remarkably similar result.
What follows is the product of nearly twenty-five years of hard lessons in the field. A translation guide. Not to make you cynical, but to help you see what is actually happening beneath the surface: because what you hear in those meetings is the tip of the iceberg. The problem is almost always underneath, in the structure of your story, not the quality of your science.
Understanding which no you are receiving, and why, is the first step to fixing it. And fixing it is exactly what the equity story is for.
I call this The Soft No Dictionary. It is the first component of The Buyer's Game, a framework for understanding how the people across the table make decisions before you walk into the room.
- VCs and pharma BD almost never say no. They use a vocabulary of polite deferrals that closes the door without the cost of closing it.
- Most rejections are not about your science. They are about committee dynamics, portfolio fit, timing, and partnerability signals you can read in advance.
- Some soft nos are structural and unavoidable. Others are avoidable with a sharper equity story, a clearer milestone map, and a defined target acquirer.
- Translating a soft no correctly tells you whether to keep pushing, reposition the ask, or move on. It saves months of chasing dead conversations.
Why nobody says no
The behaviour is rational on both sides, for different reasons.
A venture capitalist who says no definitively closes an option that costs nothing to keep open. The world is small. The fund cycle is long. The founder who looks wrong today may be right in eighteen months, and the VC who passed will want to be remembered as someone who stayed warm. A clear no also invites a conversation about why, which takes time and creates friction without upside.
A pharma BD professional faces a different constraint. They rarely have the authority to say yes alone. The decision belongs to a pipeline committee, a therapeutic area head, a business case review that meets quarterly. What the individual across the table can do is prevent your asset from advancing. What they cannot do is approve it. Their soft no is not personal. It is structural.
The numbers make this concrete. In 2024, pharma companies spent $108 billion on licensing agreements, the highest figure in a decade. But that capital was distributed across only 257 deals, down from an average of 429 per year between 2015 and 2020. More money. Fewer deals. A much higher bar per asset. Most submissions never reach a committee. They receive a phrase.
The VC half of the dictionary
Top-tier venture funds report funding roughly one in every 400 opportunities they review. The other 399 receive a phrase.
| What they say | What it means | Avoidable? |
|---|---|---|
| "We'd love to stay close to this." | No, with an option they are not paying for. If they were interested, they would propose a specific next step with a date attached. | Partly Better thesis-fit targeting reduces this significantly. |
| "The timing isn't quite right for us." | Thesis mismatch. Almost never about your timing. The fund may be at a different stage of its cycle, or there may be a competing position they are not disclosing. A better deck will not fix this. | Partly Researching fund thesis and portfolio before outreach eliminates most of these. |
| "Let's reconnect after your next milestone." | Come back when someone else has taken the risk. They want the de-risking without paying for the work it requires. | Partly A milestone map built around buyer risk thresholds, not internal operations, reduces this. |
| "We'd want to co-invest alongside a lead." | No, and finding the lead is your problem. Funds that genuinely want in will work to find a lead or offer to lead themselves. | No This reflects fund structure, not your story. |
| "Very interesting. Can you send me the deck?" | The decision was made before the deck arrived. Send it. Do not expect a response. | No |
| "We're excited about the space, but..." | Everything before "but" is decorative. Read the sentence that follows. Ignore the rest. | — Depends entirely on the sentence that follows. |
| "We have some concerns about the team." | The most honest phrase in the dictionary. When a VC says this, they usually mean it. Not always about the founders: sometimes about whether the team as currently constituted can execute the next stage. | Partly A clear leadership evolution plan in the equity story addresses this directly. |
| "We'd need to see more data." | The scientific risk has not been retired sufficiently for their thesis. The data described usually costs more to generate than the round being discussed. | Partly If your capital ask is sized around the right de-risking event for this investor, this phrase becomes less frequent. |
The pharma BD half of the dictionary
Pharma BD operates on a different logic. The committee structure distributes responsibility for rejection across an organisation, which means no individual takes the blame. What you receive are institutionally correct phrases that protect the relationship without advancing it.
| What they say | What it means | Avoidable? |
|---|---|---|
| "Very interesting science. Not in our current strategic focus." | No, and it is final. Strategic focus is decided well above the person you are meeting. If the asset does not address a named pipeline gap, the quality of the science is irrelevant. | Yes A partnerability assessment before outreach identifies which companies have the right gap at the right moment. |
| "We'll take this to our pipeline committee." | No, but it will take a month to confirm. The committee is real. What is usually missing is a champion inside the organisation willing to argue for your asset in the room. Without one, the committee sees a submission, not a proposal. | Partly Building a relationship with a potential internal champion before the formal submission changes the dynamic. |
| "We have something similar internally." | No, or a negotiating position. If true, you pitched into a conflict of interest that due diligence should have caught. If a negotiating position, it reveals what they value and what they think they can replicate without paying for it. | Yes if it is true. A competitive landscape analysis before targeting prevents this. |
| "The IP landscape looks complicated." | The freedom-to-operate analysis has unresolved questions. This is sometimes a dealbreaker and sometimes the opening of a price negotiation. Which one depends on how much they want the asset. | Partly Resolving FTO issues before outreach removes this as a reason. It may still surface as a price lever. |
| "We'd need Phase II data before a serious conversation." | Come back in three years. Their investment committee requires human proof of concept before justifying an upfront. This is not unreasonable. It is also a clear signal that you are pitching too early for this buyer, not for the asset. | Yes The right buyer for a pre-Phase II asset is not the same as the right buyer for a Phase II asset. |
| "We'd be interested in a co-development structure." | We want the economics without the upfront. Co-development deals are not inherently bad, but they are significantly different from a licensing deal with a meaningful upfront. If an upfront was what you needed, this is a no in a different envelope. | Partly A clear deal structure position in your equity story reduces ambiguity about what you are actually offering. |
| "Can you send the full data package?" | The only genuinely ambiguous phrase in the pharma BD dictionary. It means your asset has moved to a screening phase. The signal becomes meaningful only if it is followed by a call within ten days. If it is not, it was a polite close with something left in their inbox. | No t applicable. Follow up in ten days and find out. |
| "This is early for us, but keep us updated." | You are now on an unpaid newsletter list. They mean this sincerely. It is simply not a deal today. | Yes Same as "We'd need Phase II": targeting the right buyer for the current stage avoids this entirely. |
The avoidable ones
Not all of these phrases were inevitable.
Several of the softest no's in both dictionaries arrive because the conversation should never have happened in the first place, or should have happened differently. This distinction matters because the avoidable ones point directly to the equity story.
"Not in our current strategic focus" and "we have something similar internally" are targeting failures. Both are avoidable with a partnerability assessment before the first outreach: a structured analysis of which acquirers have a pipeline gap that your asset addresses, at what stage, under what deal structure, and at what price. Presenting to a pharma company without this work is the equivalent of pitching a seed fund with a Phase III asset. The science does not become relevant because the structure is wrong.
"The timing isn't right" and "we'd need to see more data" are milestone failures of a specific kind. Not about the data that exists, but about a mismatch between where the asset is and where it needs to be for this buyer's risk threshold. A development plan built around your operational logic will not fix this. A milestone map built around value inflection points that matter to a specific class of buyer might.
"We'd need Phase II before a serious conversation" and "let's reconnect after your next milestone" are both signals that you are in the right conversation at the wrong time. The question they create is not how to accelerate. It is who the right buyer is for this stage, with this data package, at this valuation.
Each of these is a question the equity story should have answered before the meeting began. Not the pitch deck. The architecture underneath it: the exit scenario, the milestone map designed around value rather than activity, the target acquirer profile built from their decision criteria rather than your aspirations, and the capital ask expressed as a specific risk retired rather than a budget consumed.
The equity story does not guarantee a yes. Nothing does. But it converts a conversation based on hope into a conversation based on alignment. And it means that when you do receive a phrase, you know precisely which kind of no it is, where it came from, and what, if anything, can be done about it.
The soft no is not a mystery. It is the gap between your story and their decision criteria, delivered politely.
Frequently asked questions
The Soft No Dictionary is the first component of The Buyer's Game, a framework for understanding how VCs and pharma business development teams evaluate assets. The other components are The Entry Conditions, The Value Clock, and The Grammar Gap.
If you are in a BD or fundraising process and the responses feel like maybes, the problem is usually in the structure of the conversation, not the quality of the asset. A 30-minute call is usually enough to diagnose it.
Book a 30-minute call